Finance

Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the company and accelerate its global vaccine strategy.

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for desmoid tumors and Gomekli for symptomatic plexiform neurofibromas.

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase I development for B cell-mediated autoimmune diseases.

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming responsibility for global development and commercialization if it exercises its option.

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity and a weight-related medical condition, but without diabetes.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene editing treatments.

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies and precision medicine for high-burden diseases.

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 billion, in addition to single-digit royalties.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions and alliances focused on pain, obesity, and neuroscience.

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the option to pursue additional indications and combination therapies independently.

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

The 700,000 square-foot facility is expected to create 400 high-wage manufacturing jobs once operational.

Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.

Navigating technology and regulatory shifts in pharma revenue management.

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly will assume responsibility for further development and commercialization of the novel platform.

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies, including antibody-drug conjugates.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

The company will be adding a new manufacturing site to its NJ campus for the drug Adstiladrin.

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in radiopharmaceutical production and distribution.